Navepegritide clinical trials
Also written TransCon CNP.
How each study uses navepegritide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the navepegritide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 Feb 2026 · YUVIWEL · NDA 219164 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Ascendis Pharma A/S (4) · Ascendis Pharma Growth Disorders A/S (2) · Visen Pharmaceuticals (Shanghai) Co., Ltd. (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test navepegritide.
- Sep 2027A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.Phase 2 · Ascendis Pharma A/S
Studies
Open first, then newest update. How each study uses navepegritide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide Versus Placebo in Children and Adolescents With HypochondroplasiaNot yet recruitingPhase 3Ascendis Pharma A/SNCT07917143Written as Navepegritide
- A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With AchondroplasiaEnrolling by invitationPhase 2/3Ascendis Pharma Growth Disorders A/SNCT05929807Written as TransCon CNP
- A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With AchondroplasiaRecruitingPhase 2Ascendis Pharma A/SNCT06079398Written as Navepegritide
- A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.Active, not recruitingPhase 2Ascendis Pharma A/SNCT06732895Written as Navepegritide
- A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Multiple Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children With AchondroplasiaCompletedPhase 2Visen Pharmaceuticals (Shanghai) Co., Ltd.NCT05246033Written as TransCon CNP
- A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With AchondroplasiaCompletedPhase 2/3Ascendis Pharma Growth Disorders A/SNCT05598320Written as Navepegritide (TransCon CNP)
- A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With AchondroplasiaCompletedPhase 2Ascendis Pharma A/SNCT04085523Written as TransCon CNP
Codes
What other systems call navepegritide · ClinicalTrials.gg INT002189
- MeSH (NLM) C000732015navepegritideOne source NLM
- UNII (FDA) Y3BH8M899DNAVEPEGRITIDEConfirmed FDA, NLM
- NCI Thesaurus C188658NavepegritideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000732015 | navepegritide | One source NLM |
| UNII (FDA) | Y3BH8M899D | NAVEPEGRITIDE | Confirmed FDA, NLM |
| NCI Thesaurus | C188658 | Navepegritide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.